je.st
news
Tag: merck
Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Companys Investigational Anti-PD-1 Antibody, at ESMO 2014
2014-09-02 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. First Presentation of Findings in Gastric and Bladder (Urothelial Tract) Cancers WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the companys investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 30. Language: English Contact: MerckMedia Contacts:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425Investor Contacts:Joseph Romanelli, 908-423-5185Justin Holko 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
present
types
studies
Pfizer to test Xalkori lung cancer drug with Merck immunotherapy
2014-08-26 18:11:28| Biotech - Topix.net
Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.
Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen
2014-08-26 16:20:33| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Agreement to Combine Mercks Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizers crizotinib (XALKORI) in Clinical Trial WHITEHOUSE STATION, N.J. Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizers crizotinib (XALKORI) with Mercks investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC). Language: English read more
Tags: study
combination
evaluating
collaborate
Advaxis, Merck to test immune therapies against prostate cancer
2014-08-25 12:19:09| Biotech - Topix.net
Advaxis Inc on Monday said it will test an experimental immuno-oncology drug in combination with a high-profile immunotherapy from Merck & Co Inc as a treatment for patients with advanced prostate cancer.
Tags: test
cancer
immune
therapies
Merck & Co. Wins U.S. FDA Approval of New Type of Sleeping Pill
2014-08-14 09:59:54| Biotech - Topix.net
Merck & Co., the second-largest U.S. drugmaker, won approval to sell its treatment for insomnia, a new type of drug considered to have fewer side effects than older pills such as Ambien.
Sites : [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] next »